###begin article-title 0
IGFBP3 Colocalizes with and Regulates Hypocretin (Orexin)
###end article-title 0
###begin p 1
Conceived and designed the experiments: MH EM. Performed the experiments: MH KSE SZ ST LL SEG ST KT. Analyzed the data: MH KSE ST LL SEG KT YH EM. Contributed reagents/materials/analysis tools: MH AS PEH JM MY TS YH EM. Wrote the paper: MH KSE SZ EM.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
The sleep disorder narcolepsy is caused by a vast reduction in neurons producing the hypocretin (orexin) neuropeptides. Based on the tight association with HLA, narcolepsy is believed to result from an autoimmune attack, but the cause of hypocretin cell loss is still unknown. We performed gene expression profiling in the hypothalamus to identify novel genes dysregulated in narcolepsy, as these may be the target of autoimmune attack or modulate hypocretin gene expression.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 124 129 <span type="species:ncbi:9606">human</span>
###xml 145 160 <span type="species:ncbi:10090">transgenic mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 257 262 <span type="species:ncbi:9606">human</span>
###xml 407 412 <span type="species:ncbi:9606">human</span>
###xml 417 422 <span type="species:ncbi:10090">mouse</span>
###xml 579 594 <span type="species:ncbi:10090">transgenic mice</span>
###xml 610 615 <span type="species:ncbi:9606">human</span>
###xml 834 839 <span type="species:ncbi:9606">human</span>
We used microarrays to compare the transcriptome in the posterior hypothalamus of (1) narcoleptic versus control postmortem human brains and (2) transgenic mice lacking hypocretin neurons versus wild type mice. Hypocretin was the most downregulated gene in human narcolepsy brains. Among many additional candidates, only one, insulin-like growth factor binding protein 3 (IGFBP3), was downregulated in both human and mouse models and co-expressed in hypocretin neurons. Functional analysis indicated decreased hypocretin messenger RNA and peptide content, and increased sleep in transgenic mice overexpressing human IGFBP3, an effect possibly mediated through decreased hypocretin promotor activity in the presence of excessive IGFBP3. Although we found no IGFBP3 autoantibodies nor a genetic association with IGFBP3 polymorphisms in human narcolepsy, we found that an IGFBP3 polymorphism known to increase serum IGFBP3 levels was associated with lower CSF hypocretin-1 in normal individuals.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 67 72 <span type="species:ncbi:10090">mouse</span>
Comparison of the transcriptome in narcolepsy and narcolepsy model mouse brains revealed a novel dysregulated gene which colocalized in hypocretin cells. Functional analysis indicated that the identified IGFBP3 is a new regulator of hypocretin cell physiology that may be involved not only in the pathophysiology of narcolepsy, but also in the regulation of sleep in normal individuals, most notably during adolescence. Further studies are required to address the hypothesis that excessive IGFBP3 expression may initiate hypocretin cell death and cause narcolepsy.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
Narcolepsy-cataplexy is a common sleep disorder affecting 0.02-0.16% of the general population in the United States, Europe and Asia. Disease onset may be insidious or abrupt, typically occurring around adolescence, and is characterized by excessive daytime sleepiness, cataplexy (sudden loss of muscle tone triggered by emotions) and other manifestations of abnormal Rapid Eye Movement (REM) sleep.
###end p 9
###begin p 10
###xml 244 253 244 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DQB1*0602</italic>
###xml 253 256 253 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Mignot1">[1]</xref>
###xml 436 439 436 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Mignot2">[2]</xref>
###xml 59 64 <span type="species:ncbi:9606">Human</span>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
Narcolepsy has characteristic biological markers including Human Leukocyte Antigen (HLA) association and dysfunction of hypocretin (also called orexin) neurotransmission. Almost all patients with narcolepsy-cataplexy share a common HLA allele, DQB1*0602[1] suggesting an autoimmune basis for the disorder. Over 90% of narcolepsy-cataplexy cases are associated with a dramatic decrease in hypocretin-1 (HCRT1) in the cerebrospinal fluid [2].
###end p 10
###begin p 11
###xml 226 229 226 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Sakurai1">[3]</xref>
###xml 476 479 476 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Chemelli1">[4]</xref>
###xml 481 484 481 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Lin1">[5]</xref>
###xml 544 548 544 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HCRT</italic>
###xml 706 709 706 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Hara1">[6]</xref>
###xml 85 90 <span type="species:ncbi:9606">human</span>
###xml 522 527 <span type="species:ncbi:10090">mouse</span>
Hypocretin-1 is a neuropeptide produced by 50,000-70,000 hypothalamic neurons in the human brain. The HCRT peptides are derived from a precursor, preprohypocretin, which is cleaved into two homologous peptides HCRT1 and HCRT2 [3]. These act on target sites through two receptors, HCRT receptor-1 and HCRT receptor-2. Deficient HCRT neurotransmission is sufficient to produce narcolepsy, as animal models with dysregulated HCRT transmission exhibit a narcolepsy-like phenotype [4], [5]. Of notable interest is a transgenic mouse model where the HCRT promoter drives a form of ataxin-3 containing a large polyglutamine repeat, resulting in HCRT cell death and a narcolepsy-like phenotype at 2-3 weeks of age [6].
###end p 11
###begin p 12
###xml 64 71 64 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In situ</italic>
###xml 128 132 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HCRT</italic>
###xml 321 324 321 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Peyron1">[7]</xref>
###xml 455 458 455 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Thannickal1">[8]</xref>
###xml 678 681 678 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Chou1">[9]</xref>
###xml 683 687 683 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Reti1">[10]</xref>
###xml 822 826 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Blouin1">[11]</xref>
###xml 828 832 828 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Crocker1">[12]</xref>
###xml 1055 1059 1055 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Thannickal2">[13]</xref>
###xml 1337 1341 1337 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Scammell1">[14]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human neuropathological studies have extended on these results. In situ hybridization (ISH) studies have shown disappearance of HCRT mRNA in the perifornical area of narcoleptic brains. Furthermore, the concentrations of HCRT1 and HCRT2 in the cortex and pons, two areas with HCRT projections, are dramatically decreased [7]. Immunohistochemical studies also revealed more than 90% decrease in HCRT cell counts in the hypothalamus of narcoleptic subjects [8]. The loss of HCRT signal is most likely not a simple failure in producing hypocretin peptides alone. Hypocretin cells contain prodynorphin (PDYN) and neuronal pentraxin II (NPTX2; Neuronal Activity-Regulated Pentraxin) [9], [10], and studies have shown that these two proteins are missing in the perifornical area, but not in other regions, of narcoleptic brains [11], [12]. This could imply that HCRT producing cells are quiescent and do not produce HCRT, PDYN and NPTX2 or, more likely, that these cells are missing entirely. Some authors have noted residual gliosis in the perifornical region [13], which combined with the strong HLA association, favors the hypothesis of autoimmune mediated destruction of HCRT neurons. However, most attempts to prove the autoimmune hypothesis, for example through the detection of HCRT-cell specific autoantibodies, have been unsuccessful [14].
###end p 12
###begin p 13
###xml 316 321 <span type="species:ncbi:9606">human</span>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
A deeper understanding of HCRT cell physiology is required, including the identification of genes and proteins that may be the target of an autoimmune attack or may modulate hypocretin expression/metabolism to make this cell population more susceptible to potential apoptosis. In this study, we have used postmortem human brain samples to compare the transcriptome of narcoleptic versus control subjects, with confirmation in animal models of narcolepsy. Our primary goal was to identify other genes and associated proteins that may be dysregulated in the posterior hypothalamus of narcoleptic patients, potentially expressed in HCRT neurons, as such genes are likely to be novel narcolepsy susceptibility genes.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
Identification of brain region specific transcripts
###end title 15
###begin p 16
###xml 75 82 75 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t001">Table 1</xref>
###xml 239 247 239 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004254.s001">Table S1</xref>
###xml 922 930 919 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004254.s001">Table S1</xref>
A total of 11 control and 6 narcolepsy brains were analyzed by microarray (Table 1). To validate our methods, we first compared transcript abundance across brain regions in control samples and identified brain region specific transcripts (Table S1). Of the 7 identified genes with putative preferential expression in the posterior hypothalamus, three are known to be restricted to this region: prepromelanin concentrating hormone, preprohypocretin, and histidine decarboxylase. Likewise, arginine vasopressin and oxytocin are expressed in the anterior hypothalamus. In the locus coeruleus (LC) where 14 genes were found to be region specific, seven, including dopamine-beta-hydroxylase and tyrosine hydroxylase, are known to be expressed specifically in the LC. These results offered a strong validation of sample selection, dissection, array experiment procedure and the statistical analysis methods used in this study. (Table S1)
###end p 16
###begin title 17
###xml 36 41 <span type="species:ncbi:9606">human</span>
Demographic and RNA quality data of human brain tissue used for analysis.
###end title 17
###begin p 18
Age and gender distribution, postmortem interval (PMI) and brain pH are not significantly different between narcoleptic subjects (N4-N101) and controls (C1-C16).
###end p 18
###begin title 19
###xml 46 51 <span type="species:ncbi:9606">human</span>
Identification of transcripts dysregulated in human narcolepsy
###end title 19
###begin p 20
###xml 32 34 32 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
###xml 439 443 439 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Tusher1">[15]</xref>
###xml 1017 1024 1017 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t002">Table 2</xref>
In the comparison of narcolepsy vs control posterior hypothalami, a total of 35 downregulated and 11 upregulated genes were identified by analysis of microarray expression data. Of these, only nine genes were confirmed by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (QRT-PCR), all of which were downregulated in narcolepsy. Hypocretin was the most significantly decreased gene by Significance Analysis of Microarray (SAM) [15] ranking, and was second in terms of mean fold change. QRT-PCR confirmation indicated a dramatic 57.4 fold decrease in preprohypocretin transcript abundance, identifying the known central feature of narcolepsy. The eight other confirmed candidates, leiomodin 1 (LMOD1), cold shock domain protein A (CSDA), G protein-coupled receptor 4 (GPR4), endothelin 1 (EDN1), neuropeptide Y (NPY), growth arrest and DNA-damage-inducible, beta (GADD45B), interleukin 1 recptor-like 1 (IL1RL1) and insulin-like growth factor binding protein 3 (IGFBP3) were downregulated 1.6 to 6.1 fold (Table 2).
###end p 20
###begin title 21
###xml 118 125 118 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
Human narcolepsy susceptibility candidate genes analyzed by microarray, quantitative RT-PCR and distribution shown by in situ hybridization in mice.
###end title 21
###begin p 22
n.t.; not tested, n.e.; no expression, n.c.; no coexpression in perifornical hypocretin area.
###end p 22
###begin p 23
probe set ID is from aAffymetrix, QRT-PCR probe ID is from Applied Biosystems, and All clones for in situ hybridization are IMAGE clones except where noted.
###end p 23
###begin p 24
###xml 279 286 279 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 526 532 526 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 304 309 <span type="species:ncbi:10090">mouse</span>
Gene expression was compared between 6 narcolepsy and 8 control postmortem posterior hyptothalami (A and B Genechip). Narcolepsy candidate genes selected by statistical analysis of microarray data are listed at left, quantitative RT-PCR results are in the center, and results of in situ hybridization in mouse hypothalamus are at the right. As only downregulated genes were confirmed by RT-PCR studies, upregulated candidates are not shown. Genes labeled with "validated" were confirmed as narcolepsy related genes. Note that IGFBP3 is the only gene validated by QRT-PCR and showing a hypocretin-like distribution pattern. Some candidates showed uniform signal over the whole brain section, potentially indicating ubiquitous expression, but we regarded the staining as background and classified the gene as not expressed if no anatomical variation in staining level was observed.
###end p 24
###begin p 25
###xml 153 158 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NPTX2</italic>
###xml 160 163 160 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAL</italic>
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CART</italic>
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PDYN</italic>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PDYN</italic>
###xml 414 419 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NPTX2</italic>
###xml 440 443 440 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAL</italic>
###xml 465 469 465 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CART</italic>
###xml 524 528 524 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PDYN</italic>
###xml 550 555 550 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NPTX2</italic>
###xml 577 580 577 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAL</italic>
###xml 602 606 602 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CART</italic>
Previously known HCRT co-expressed genes were not reported in our analysis either because they were not listed within the top 100 SAM ranked candidates (NPTX2, GAL (galanin), and CART (cocaine and amphetamine regulated transcript), or expression was classified as "absent" (PDYN) using the microarray suite software (MAS) 5.0 algorithm. The array signals for these genes were decreased (PDYN: 2.4 fold, p = 0.005; NPTX2: 1.3 fold, p = 0.5; GAL: 2.3 fold, p = 0.06; CART: 1.2 fold, p = 0.36) as were the QRT-PCR comparisons (PDYN: 1.8 fold, p = 0.03; NPTX2: 1.6 fold, p = 0.07; GAL: 1.9 fold, p = 0.09; CART: 1.3 fold, p = 0.24). These results further validated our method.
###end p 25
###begin title 26
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
IGFBP3 is co-localized in hypocretin producing cells in mouse brains
###end title 26
###begin p 27
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In situ</italic>
###xml 105 112 105 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t002">Table 2</xref>
###xml 256 263 256 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp 3</italic>
###xml 346 353 346 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t002">Table 2</xref>
###xml 355 361 355 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g001">Fig. 1</xref>
###xml 537 544 537 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t002">Table 2</xref>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
In situ hybridization (ISH) of all human putative downregulated genes was performed in mice (C57/BL/6J) (Table 2). Of the 8 candidates confirmed by QRT-PCR as downregulated in narcolepsy brains, only one gene, Insulin-like Growth Factor Binding Protein-3 (Igfbp 3), was clearly enriched in the perifornical region where HCRT neurons are located (Table 2, Fig. 1). Among the other genes, many did not appear to be expressed at all in the studied brain regions or the expression was restricted to regions other than the perifornical area (Table 2).
###end p 27
###begin title 28
###xml 68 72 <span type="species:ncbi:10090">mice</span>
IGFBP3 signals in wild type, ataxin-3 hemizygous, and hypocretin KO mice.
###end title 28
###begin p 29
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 207 212 <span type="species:ncbi:10090">mouse</span>
###xml 472 477 <span type="species:ncbi:10090">mouse</span>
The upper panel shows IGFBP3 ISH staining in wild type (A: WT), ataxin-3 hemizygous (B:HZ) and HCRT knockout (C: KO) mice. HCRT staining in neurons (arrowheads) is markedly reduced or absent in the ataxin-3 mouse. The lower panel shows IGFPB3 ISH signal (D: purple; digoxigenin staining with BCIP/NBT), HCRT fluorescence (E: red; Alexa Fluor) immunostaining, and a composite picture (F), indicating that many hypocretin neurons (asterisks) are positive for IGFBP3 in a WT mouse. Scale bar 20 microm.
###end p 29
###begin p 30
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 139 142 139 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Hara1">[6]</xref>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 173 176 173 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Chemelli1">[4]</xref>
###xml 205 207 205 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 443 449 443 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g001">Fig. 1</xref>
###xml 595 599 595 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 623 629 623 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp3</italic>
###xml 673 679 673 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g001">Fig. 1</xref>
###xml 751 757 751 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp3</italic>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
###xml 354 358 <span type="species:ncbi:10090">mice</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
###xml 603 607 <span type="species:ncbi:10090">mice</span>
###xml 667 671 <span type="species:ncbi:10090">mice</span>
To determine if IGFPB3 is selectively expressed by HCRT neurons in the perifornical area, we used Hcrt-ataxin-3 hemizygous (HZ) transgenic [6], and Hcrt knock-out (KO) mice [4]. When we performed ISH with 35S-probes and exposed X-ray film to these slides, signal in the perifornical area was visible after 4 day exposure in the littermate wild type (WT) mice, whereas this region remained invisible after 40 days of exposure in ataxin-3 mice (Fig. 1). Loss of HCRT peptide in ataxin-3 mice could potentially induce secondary changes in gene expression in neighboring cells. Therefore we studied Hcrt KO mice and found that Igfbp3 expression was similar to that of WT mice (Fig. 1) indicating that loss of HCRT peptide itself did not induce changes in Igfbp3 expression.
###end p 30
###begin p 31
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp3</italic>
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp3</italic>
###xml 201 207 189 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g001">Fig. 1</xref>
###xml 249 255 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp3</italic>
###xml 307 313 295 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp3</italic>
###xml 737 741 725 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 282 287 <span type="species:ncbi:10090">mouse</span>
###xml 767 771 <span type="species:ncbi:10090">mice</span>
To investigate coexpression of HCRT and Igfbp3, we performed Igfbp3 ISH followed by HCRT immunostaining. Colocalization of both signals was seen in a majority (approximately80%) of hypocretin neurons (Fig. 1). Using this technique, we also surveyed Igfbp3 expression throughout the mouse brain. Significant Igfbp3 expression was restricted to a few brain areas including posterior hypothalamus, cerebellar Purkinje neurons, and a group of cells in the pons localized in or close to the pedunculopontine nucleus. Weaker signal was also seen in the ventromedial hypothalamus, granular and pyramidal layers of the hippocampus, and endopiriform nucleus. Expression in all regions other than posterior hypothalamic area was unaffected in the Hcrt-ataxin-3 hemizygous (HZ) mice.
###end p 31
###begin title 32
###xml 23 28 <span type="species:ncbi:9606">human</span>
IGFBP3 is localized in human hypocretin producing cells
###end title 32
###begin p 33
###xml 589 595 589 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g002">Fig. 2</xref>
###xml 126 131 <span type="species:ncbi:9606">human</span>
###xml 879 887 <span type="species:ncbi:9606">patients</span>
IGFBP3 immunoreactivity was surveyed using various antibodies (after screening selectivity by western blot) through an entire human hypothalamic block. Blood vessels gave strong signal with IGFBP3 antibody, possibly due to residual blood which has very high IGFBP3 content. Other cells, mostly of non-neuronal origin and negative for the NeuN neuronal marker were also stained. Cellular IGFBP3 staining of NeuN positive large neurons was only noted in the perifornical area. IGFBP3 and HCRT double immunostaining detected colocalization in 10-20% of HCRT neurons in the perifornical area (Fig. 2). All neurons showing colocalization of IGFBP3 and HCRT appeared to have a reduced hypocretin signal. Double-stained fibers were also observed in multiple other hypothalamic areas. This colocalization was also seen in some of the few remaining HCRT neurons in brains from narcolepsy patients.
###end p 33
###begin title 34
###xml 65 70 <span type="species:ncbi:9606">human</span>
Colocalization of IGFBP3 in HCRT cells in control and narcolepsy human brain.
###end title 34
###begin p 35
###xml 85 90 <span type="species:ncbi:9606">human</span>
Upper panel: Distribution of hypocretin cells and fibers in the perifornical area of human hypothalamus. (A) In control brains, HCRT cells and fibers were densely stained by an anti-HCRT monoclonal antibody (red fluorescence: VectorRed), while in narcolepsy brains, staining was markedly reduced (B) Lower panel: HCRT immunoreactivity (C: red fluorescence) and IGFBP3 immunoreactivity (D: green fluorescene; Q-dot525) and a composite picture (E) arrows indicate HCRT cells colocalized with IGFBP3). Note non-neuronal autofluorescent elements. Scale bar: 500 microm in A and B, 100 microm in C, D and E.
###end p 35
###begin title 36
###xml 93 98 <span type="species:ncbi:10090">mouse</span>
Identification of transcripts downregulated in the hypocretin-ataxin-3 hemizygous transgenic mouse model
###end title 36
###begin p 37
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 240 247 240 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t003">Table 3</xref>
###xml 388 395 388 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t003">Table 3</xref>
###xml 85 100 <span type="species:ncbi:10090">transgenic mice</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 446 451 <span type="species:ncbi:9606">human</span>
Gene expression in perifornical posterior hypothalamus was compared in Hcrt-ataxin-3 transgenic mice lacking most hypocretin neurons versus wild type animals (two pools of 30 mice). Transcripts with the highest fold changes are reported in Table 3. Genes with known colocalization, such as NPTX2 and dynorphin, were downregulated, validating the model. Other transcripts were also found (Table 3), only one of which, IGFBP3, was downregulated in human narcolepsy hypothalami. For this reason, functional studies involving IGFBP3 and hypocretin were next carried out.
###end p 37
###begin title 38
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
Mouse transcripts most differentially dysregulated in the perifornical area of ataxin-3 transgenic animals versus control mice.
###end title 38
###begin p 39
###xml 113 120 113 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004254.s003">Fig. S1</xref>
###xml 176 180 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 320 324 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 54 69 <span type="species:ncbi:10090">transgenic mice</span>
###xml 201 206 <span type="species:ncbi:10090">mouse</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 487 492 <span type="species:ncbi:9606">human</span>
The perifornical area of 30 wild type and 30 ataxin-3 transgenic mice lacking hypocretin cells were punched (see Fig. S1) and samples pooled to perform microarray experiments. Hcrt-ataxin-3 transgenic mouse dysregulated genes are listed by order of transcript abundance (fold change). Most transcripts were decreased in Hcrt-ataxin-3 mice, some of which are known to be colocalized with hypocretin (NPTX2, dynorphin). Note that IGFBP3, which was identified by expression profiling using human hypothalami, was also decreased in this experiment.
###end p 39
###begin title 40
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Evaluation of IGFBP3 levels, genotype, and IGFBP3 antibodies in blood and CSF of narcoleptic patients
###end title 40
###begin p 41
###xml 396 400 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Bunn1">[16]</xref>
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
We investigated whether human narcolepsy is associated with dysregulated IGFBP3 levels in the blood and CSF. Mean levels of IGFBP3 in age and sex matched narcolepsy patients (all with low CSF hypocretin-1) versus controls were 59.4+/-3.4 ng/ml (n = 11) and 58.0+/-4.5 (n = 11) ng/ml in serum and 31.2+/-2.1 ng/ml (n = 27) and 29.0+/-1.9 ng/ml (n = 35) in CSF respectively. As previously reported [16], levels of IGFBP3 correlated with age but not sex in adults. After controlling for these factors, there was no significant difference in age of onset.
###end p 41
###begin p 42
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 109 113 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Jernstrom1">[17]</xref>
###xml 184 189 <span type="species:ncbi:9606">human</span>
A single base polymorphism in the IGFBP3 promoter region (rs 2854744) strongly correlates with plasma IGFBP3 [17] levels. We tested whether this IGFBP3 polymorphism is associated with human narcolepsy-cataplexy by testing 130 trios using the transmission disequilibrium test (TDT). No difference in transmission was observed (53.5% versus 46.5% for the A allele; Chi sq = 0.77, p = 0.38).
###end p 42
###begin p 43
###xml 111 116 <span type="species:ncbi:9606">human</span>
###xml 238 243 <span type="species:ncbi:9606">human</span>
###xml 303 308 <span type="species:ncbi:9606">human</span>
###xml 326 334 <span type="species:ncbi:9606">patients</span>
We also explored the possibility that autoantibodies directed against IGFBP3 could be identified. We expressed human IGFBP3 in COS cells, and extracted proteins were western blotted. The resulting membrane was incubated with sera from 22 human narcoleptic and 20 control subjects and revealed with anti human IgG. None of the patients (some with disease onset less than a year prior to blood sampling) or controls had specific reactivity to expressed IGFBP3.
###end p 43
###begin title 44
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
IGFBP3 inhibits hypocretin production in vivo
###end title 44
###begin p 45
###xml 77 84 77 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 119 129 119 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mIgfbp3 KO</italic>
###xml 148 152 148 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Ning1">[18]</xref>
###xml 206 210 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Modric1">[19]</xref>
###xml 267 274 267 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 377 387 377 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hmutIGFBP3</italic>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Silha1">[20]</xref>
###xml 602 608 602 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 649 656 649 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 692 702 692 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hmutIGFBP3</italic>
###xml 897 903 897 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp3</italic>
###xml 1045 1054 1045 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g003">Fig. 3A&#8211;C</xref>
###xml 1135 1142 1135 1142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 1229 1239 1229 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hmutIGFBP3</italic>
###xml 1255 1261 1255 1261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp3</italic>
###xml 1271 1280 1271 1280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g003">Fig 3A, C</xref>
###xml 1355 1362 1355 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 1389 1399 1389 1399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">humtIGFBP3</italic>
###xml 1552 1558 1552 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g003">Fig 3B</xref>
###xml 1615 1622 1615 1622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 1827 1834 1821 1828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 1853 1859 1847 1853 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp3</italic>
###xml 1869 1876 1863 1870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g003">Fig. 3D</xref>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 161 166 <span type="species:ncbi:9606">human</span>
###xml 225 230 <span type="species:ncbi:10090">mouse</span>
###xml 253 258 <span type="species:ncbi:9606">human</span>
###xml 526 531 <span type="species:ncbi:9606">human</span>
###xml 1265 1269 <span type="species:ncbi:10090">mice</span>
###xml 1400 1415 <span type="species:ncbi:10090">transgenic mice</span>
To investigate whether IGFBP3 regulates hypocretin cell physiology and sleep in vivo, we studied IGFBP3 knockout mice (mIgfbp3 KO: C57BL/6J strain) [18] and two human IGFBP3 transgenic lines ( CD-1 strain) [19]: a transgenic mouse strain overexpressing human IGFBP3 (hIGFBP3 transgenic), and a transgenic strain overexpressing a mutated form of hIGFBP3 that does not bind IGF (hmutIGFBP3 transgenic) [20]. These two lines allowed us to distinguish IGF dependent and independent effects of IGFBP3. Quantitative PCR analysis of human IGFBP3 transcripts in the hypothalamus of these models indicated that IGFBP3 is overexpressed approximately twice in hIGFBP3 transgenic animals and 10 times in hmutIGFBP3 transgenic animals, but is absent in IGFBP3 knockout animals (data not shown), validating these models. Immunocytochemistry did not reveal hypocretin cell defects nor decrease in cell number in Igfbp3 knockout or transgenic animals (data not shown). We next measured hypocretin-1 peptide content and hypothalamic preprohypocretin expression (Fig. 3A-C) and found that preprohypocretin mRNA expression was significantly decreased in hIGFBP3 transgenic animals compared to controls, but unaltered in the other models (including hmutIGFBP3 transgenic and Igfbp3 KO mice)(Fig 3A, C). Hypocretin-1 peptide contents were significantly decreased primarily in hIGFBP3 transgenic and less so in humtIGFBP3 transgenic mice compared to controls, indicating both IGF dependent and less prominently independent properties of IGFBP3 affect hypocretin production (Fig 3B). Hypocretin cell counts were nonetheless normal in the hIGFBP3 transgenic model (3269+/-99 in HZ versus3230+/-140 in WT, n = 4 each, age 8 weeks, mean+/-SEM). As a control, Melanin Concentrating Hormone (MCH) expression was also studied and found to be unaffected by hIGFBP3 overexpression or Igfbp3 absence (Fig. 3D).
###end p 45
###begin title 46
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 44 52 44 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
IGFBP3 inhibits HCRT production in vivo and in vitro.
###end title 46
###begin p 47
###xml 141 147 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 377 383 377 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 408 414 408 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 463 469 463 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 480 486 480 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 123 138 <span type="species:ncbi:10090">transgenic mice</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 672 677 <span type="species:ncbi:9606">human</span>
(A, B) Hypocretin-1 peptide content is significantly decreased in both hypothalamus and brainstem of IGFBP3 overexpressing transgenic mice (hIGFBP3 TG). In mutant IGFBP3 overexpressing mice (hmutIGFBP3 TG), the hypocretin-1 peptide shows slight but significant decrease only in brainstem, not in hypothalamus (A, B). Hypocretin mRNA is also significantly decreased in IGFBP3 (hIGFBP3 TG) mice but not in hmutIGFBP3 TG mice. (C) MCH mRNA level is not affected in hIGFBP3 TG or hmutIGFBP3 TG TG mice.(D) IGFBP3 expression reduces preprohypocretin promotor activity in the SH-SY5Y neuroblastoma cell line, but not in non-neural cell lines (HeLa, HEK, SF126, Becker). (F). In human subjects, rs2854744, -202 C, a promotor polymorphism allele known to be associated with reduced IGFBP3 production, is dose dependently associated with increased CSF hypocretin-1 levels. A, B: *: p<0.05; **, p<0.01; ***:p<0.001; C: *: p<0.001 versus without 3.2 kb promotor activity, #:p<0.001 versus promotor activity without IGFBP3; F: *: p<0.05 using ANOVA with genotype as a grouping factor. Sample numbers were indicated in parentheses.
###end p 47
###begin title 48
IGFBP3 overexpression increases sleep at the end of the active period
###end title 48
###begin p 49
###xml 67 74 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 109 113 109 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 278 285 278 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 361 365 357 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 375 382 371 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 567 574 563 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 689 697 685 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004254.s002">Table S2</xref>
###xml 945 951 941 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g004">Fig. 4</xref>
###xml 990 997 986 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mIgfbp3</italic>
###xml 1114 1120 1110 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g003">Fig. 3</xref>
###xml 75 90 <span type="species:ncbi:10090">transgenic mice</span>
###xml 123 138 <span type="species:ncbi:10090">transgenic mice</span>
###xml 575 590 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1001 1005 <span type="species:ncbi:10090">mice</span>
To assess whether IGFBP3 overexpression could modulate cell death, hIGFBP3 transgenic mice were crossed with Hcrt-ataxin-3 transgenic mice known to develop hypocretin cell loss at 3-6 weeks of age. Hypocretin cell counts were carried out at 8 weeks of age, and no effect of the hIGFBP3 transgene was noted (595+/-36 in double HZ (hemizygous) versus 610+/-67 in Hcrt-ataxin-3/hIGFBP3 HZ/WT, n = 5 each). We next characterized whether overexpression of IGFBP3 and resulting effects on hypocretin transmission affect sleep and wakefulness by conducting sleep studies on hIGFBP3 transgenic mice and their littermates. Although no overall significant difference in sleep amounts were observed (Table S2), we found that these animals exhibit more sleep at the end of the dark period. Sleep deprivation was also performed, and revealed a very similar recovery profile, although more sleep was again observed in transgenic animals prior to light onset (Fig. 4). Sleep studies were not performed on mIgfbp3 KO mice considering the absence of significant differences in Hypocretin mRNA and peptide content in these animals (Fig. 3).
###end p 49
###begin title 50
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 38 53 <span type="species:ncbi:10090">transgenic mice</span>
Decreased wakfeluness in human IGFBP3 transgenic mice.
###end title 50
###begin p 51
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 540 547 540 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004254.s004">Fig. S2</xref>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 101 106 <span type="species:ncbi:10090">mouse</span>
###xml 377 392 <span type="species:ncbi:10090">transgenic mice</span>
(A) Wakefulness is decreased in the second half of the dark/active period in human IGFBP3 transgenic mouse (hIGFBP3 TG) versus wild type littermates (WT). Reduced sleep rebound is also observed at the same Zeitgeber times (ZT) after sleep deprivation. (B) Cumulative NREM plots at baseline and during recovery after 6 hours of sleep deprivation. Note increased sleep in IGFBP3 transgenic mice in the second half of the active period, ZT17-24. **: p<0.01 versus WT; ***: p<0.001 versus WT. Temperature and locomotion were also affected, see Fig. S2.
###end p 51
###begin title 52
IGFBP3 reduces promotor activity of hypocretin in neural cell lines
###end title 52
###begin p 53
###xml 106 110 106 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Lee1">[21]</xref>
###xml 395 402 395 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g003">Fig. 3E</xref>
###xml 472 480 472 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
As IGFBP3 is known to have modulatory effects on transcription, for example through its binding to nur 77 [21], a possible explanation for IGFBP3 effects on sleep could be transcriptional modulation of the preprohypocretin gene. To test this hypothesis, prepro-hypocretin promotor activity was examined in several cell lines of various origins in the presence of a transfected IGFBP3 construct (Fig. 3E). We found that IGFBP3 reduced promotor activity of preprohypocretin in vitro. This effect was only observed in the neural (neuroblastoma-derived) cell line SH-SY5Y, suggesting the need for neural-specific cofactors.
###end p 53
###begin title 54
An IGFBP3 polymorphism known to increase IGFBP3 serum levels is associated with reduced CSF hypocretin levels
###end title 54
###begin p 55
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 654 661 654 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g003">Fig. 3F</xref>
###xml 748 755 748 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 759 765 <span type="species:ncbi:9606">humans</span>
To test whether IGFBP3 activity regulates hypocretin levels in vivo, DNA samples of 262 Caucasian subjects with normal CSF hypocretin-1 levels (>200 pg/ml), either drawn from healthy control subjects or from subjects with a complaint of sleepiness unexplained by hypocretin deficiency, were typed for rs2854744 (-202A/C IGFBP3 promoter polymorphism). As previously reported, no relationship between sleepiness/disease status, age or sex and hypocretin levels were found. Interestingly however, a significant dose dependent increase in hypocretin-1 level was found with increasing doses of rs2854744 C, the allele associated with decreased IGFBP3 levels (Fig. 3F). These results suggest that this IGFBP3 polymorphism modulates hypocretin production in vivo in humans.
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 116 120 116 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Franz1">[22]</xref>
###xml 40 45 <span type="species:ncbi:9606">human</span>
Gene expression profiling in postmortem human brain samples using microarrays is a difficult and controversial area [22]. To validate our technique, we compared transcript abundance in regions known to contain specific neurotransmitters of importance in sleep regulation. After filtering out genes with inconsistent expression, a combination of a permutation method (SAM) and descriptive quantitative ranking of fold changes was found to be the most appropriate statistical analysis. The anterior and posterior hypothalami are known to promote sleep and wake respectively. The LC area was selected as a prototypical HCRT receptor-1 bearing adrenergic cell group, while the diagonal band was selected as an HCRT receptor-2 rich area containing cholinergic neurons.
###end p 57
###begin p 58
###xml 105 113 105 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004254.s001">Table S1</xref>
###xml 197 199 193 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2A</sub>
###xml 378 384 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PHOX2A</italic>
###xml 389 395 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PHOX2B</italic>
###xml 450 454 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-VogelHopker1">[23]</xref>
The comparison of regions showed a remarkably high expression of genes characteristic for these regions (Table S1). In the LC, for example, enriched genes included the presynaptically located alpha2A- receptors and adrenergic transporters, catecholamine synthesizing enzymes (tyrosine hydroxylase, DOPA decarboxylase and dopamine-beta-hydroxylase) and the transcription factors PHOX2A and PHOX2B which are involved in the development of this nucleus [23]. Additional work is indicated to validate and study these genes, as they are potentially important in the neurobiology of these regions. It is notable that our study compared only four regions but was sufficient to effectively identify a large number of region-specific genes.
###end p 58
###begin p 59
###xml 147 154 147 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t002">Table 2</xref>
###xml 687 694 687 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t002">Table 2</xref>
###xml 1049 1053 1049 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Mandel1">[24]</xref>
###xml 481 489 <span type="species:ncbi:9606">patients</span>
These promising results led us to compare narcolepsy and control posterior hypothalamus, the primary site of the biochemical defect in narcolepsy (Table 2). In this comparison we used slightly less stringent criteria with inclusion of the top 100 SAM dysregulated genes followed by QRT-PCR validation using the same brain sample sets. No genes were confirmed to be upregulated, whereas 9 of 35 candidates were confirmed as downregulated in the posterior hypothalamus of narcolepsy patients. As expected, preprohypocretin was the top candidate in this analysis, displaying a 9-fold change in expression through the array comparison and a more than 50 fold change when verified by RT-PCR (Table 2). This striking result suggests that if this precise neuroanatomical region had been targeted, it would have been possible to discover the central feature of narcolepsy -HCRT deficiency- without a preconceived hypothesis. A recent microarray analysis in Parkinson's disease also yielded excellent results after careful dissection of the substantia nigra [24]. Our work thus validates the use of postmortem samples for finding the cause of certain neuropsychiatric disorders, a nascent field, provided that careful selection of neuroanatomical regions is performed, as in these studies.
###end p 59
###begin p 60
###xml 409 414 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTPX2</italic>
###xml 416 419 416 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAL</italic>
###xml 421 425 421 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PDYN</italic>
###xml 427 433 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD3</italic>
###xml 489 493 489 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CART</italic>
###xml 650 655 650 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NPTX2</italic>
###xml 657 660 657 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAL</italic>
###xml 662 666 662 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CART</italic>
###xml 736 740 736 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PDYN</italic>
###xml 742 748 742 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ENTPD3</italic>
###xml 857 864 857 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">results</xref>
###xml 90 95 <span type="species:ncbi:10090">mouse</span>
###xml 540 545 <span type="species:ncbi:9606">human</span>
The posterior hypothalamic candidates were also subjected to neuroanatomical screening in mouse brain. The primary goal of this analysis was to identify genes that are coexpressed with HCRT and therefore lost in narcoleptic brains in association with death of these cells. Very few such candidates are currently known, and none is specific for HCRT neurons. Known coexpressed genes in various species include NTPX2, GAL, PDYN, ENTPD3 (extonucleoside triphosphate diphosphohydrolase 3) and CART. These transcripts were not identified in our human array analysis as they either were expressed in other areas of the brain, leading to a low SAM ranking (NPTX2, GAL, CART) or because the expression was classified as absent in most samples (PDYN, ENTPD3), although the QRT-PCR analysis indicated moderately decreased expression of these genes in narcolepsy (see results).
###end p 60
###begin p 61
###xml 137 143 137 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 169 173 169 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HCRT</italic>
###xml 333 339 333 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g001">Fig. 1</xref>
###xml 352 358 352 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g002">Fig. 2</xref>
###xml 408 414 408 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp3</italic>
###xml 543 549 531 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp3</italic>
###xml 626 630 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
###xml 182 188 <span type="species:ncbi:9606">humans</span>
###xml 193 197 <span type="species:ncbi:10090">mice</span>
###xml 326 331 <span type="species:ncbi:10090">mouse</span>
###xml 345 350 <span type="species:ncbi:9606">human</span>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
###xml 651 656 <span type="species:ncbi:10090">mouse</span>
A combination of QRT-PCR confirmation in human hypothalamus and neuroanatomical screening in the mouse brain identified a single factor, IGFBP3 that is coexpressed with HCRT in both humans and mice and present in only a few other brain areas. Confirmation of the colocalization was performed using multiple techniques in both mouse (Fig. 1) and human (Fig. 2). A combination of ISH and immunostaining showed Igfbp3 expression in a majority (approximately80%) of HCRT neurons in mice. One of the most striking findings was the observation that Igfbp3 signal decreased dramatically in the perifornical hypocretin cell region of Hcrt-ataxin-3 transgenic mouse lacking most hypocretin producing cells.
###end p 61
###begin p 62
###xml 268 275 268 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 620 626 620 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL1RL1</italic>
###xml 757 761 757 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Coyle1">[25]</xref>
###xml 852 858 852 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">eg NPY</italic>
###xml 860 864 860 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GPR4</italic>
###xml 52 57 <span type="species:ncbi:9606">human</span>
###xml 293 297 <span type="species:ncbi:10090">mice</span>
###xml 589 594 <span type="species:ncbi:9606">human</span>
Although the other 7 QRT-PCR confirmed genes in the human study were not found to be expressed in HCRT neurons, additional work will be needed to explore the importance of these genes in the pathophysiology of narcolepsy. In some cases, expression was not detected by in situ hybridization in mice but may still be present at low levels. Further, hypocretin cell loss in narcolepsy might be triggered by yet unknown changes in surrounding cells or structures. These factors would not be identified in animal models with disrupted hypocretin neurotransmission but would be downregulated in human brains. In this respect, IL1RL1 may be of special interest as we found a 6.1 fold difference by QRT-PCR, and this orphan receptor has a role in immune regulation [25]. The other downregulated genes that were found, or previously known to express elsewhere (eg NPY, GPR4), may reflect physiologically important network remodeling in narcolepsy.
###end p 62
###begin p 63
###xml 428 432 428 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Lee2">[26]</xref>
###xml 837 843 837 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 938 942 938 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Beilharz1">[27]</xref>
###xml 99 104 <span type="species:ncbi:9606">human</span>
###xml 990 996 <span type="species:ncbi:9606">humans</span>
###xml 1001 1005 <span type="species:ncbi:10090">mice</span>
Double immunostaining also revealed additional IGFBP3 immunoreactive, hypocretin negative cells in human hypothalamus (both neurons and glial cells). The IGFBP3 protein is primarily produced and secreted by the liver and is the major carrier of insulin-like growth factors 1 and 2 (IGF1, IGF2) in the blood. The resulting IGFBP3-IGF complex is typically taken up by cells through IGF receptor 1 to produce intracellular effects [26]. In this context, uptake of IGFBP3 by brain cells could render them immunoreactive without accompanying gene expression. We found that CSF levels of IGFBP3 were high, suggesting significant translocation from serum into brain extracellular fluid. Other explanations could involve antibody specificity issues and relative differences in abundance between protein and mRNA in different cells. Induction of IGFBP3 expression can occur in neurons and glial cells under various conditions, for example hypoxia [27], and this might also cause differences between humans and mice.
###end p 63
###begin p 64
###xml 299 304 <span type="species:ncbi:9606">human</span>
###xml 433 438 <span type="species:ncbi:9606">human</span>
What function could IGFBP3 have in hypocretin producing cells with regard to narcolepsy? As the protein is co-localized with HCRT, IGFBP3 could have been an autoantigen involved in the hypothesized autoimmune attack directed against the HCRT neurons. We found no evidence for such autoantibodies in human sera and CSF, however. IGFBP3 levels were similar in CSF and serum of narcolepsy versus controls, and it is abundant in various human brain cells, possibly reflecting cellular uptake of circulating IGFBP3. These make it an unlikely candidate in directing an autoimmune process specifically toward HCRT neurons.
###end p 64
###begin p 65
###xml 181 185 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Fang1">[28]</xref>
###xml 605 609 605 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Kim1">[29]</xref>
###xml 620 624 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Bhattacharyya1">[30]</xref>
###xml 643 647 643 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Santer1">[31]</xref>
###xml 947 951 935 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Lee1">[21]</xref>
###xml 1021 1030 1009 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g002">Fig 2 D,E</xref>
###xml 997 1002 <span type="species:ncbi:9606">human</span>
Even if not directly involved as an autoantigen in causing narcolepsy, IGFBP3 is still an interesting candidate as it plays key roles in regulating cell proliferation and apoptosis [28]. The interaction of IGFBP3 with IGFs is generally believed to have primarily pro-growth effects by favoring target availability of IGF, but growth-inhibiting effects have also been noted. IGFBP3 is also reported to have proapoptotic properties independent of IGF-binding. For example, IGFBP3 expression in cancer cells and in the circulation is associated with less malignant growth and decreased cancer risk in breast [29], prostate [30] and other cancers [31]. Of note, the proapoptotic effects commence with IGFBP3 translocation into the nucleus and binding of the retinoid-X-receptor-alpha (RXRalpha), with subsequent mobilization of the RXRalpha binding partner Nur77 from the nucleus to mitochondria, an event followed by caspase activation and apoptosis [21]. We found no intranuclear IGFBP3 staining in human hypocretin cells (Fig 2 D,E), suggesting no proapoptotic effects in surviving hypocretin cells.
###end p 65
###begin p 66
###xml 198 202 198 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Bhattacharyya1">[30]</xref>
###xml 481 485 481 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Katsuki1">[32]</xref>
###xml 595 599 595 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 732 739 732 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 907 909 907 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
###xml 609 624 <span type="species:ncbi:10090">transgenic mice</span>
###xml 687 702 <span type="species:ncbi:10090">transgenic mice</span>
###xml 718 723 <span type="species:ncbi:9606">human</span>
Recently however, proapoptotic effects of IGFBP3 independent of nuclear translocation and protein secretion have been demonstrated, suggesting additional cytoplasmic pathways also promote apoptosis [30]. It is thus possible that IGFBP3 produced within hypocretin cells would not be bound to IGFs, potentially increasing vulnerability to proapoptotic processes. Indeed, hypocretin neurons in slice cultures are more sensitive than neighboring cells to NMDA receptor-mediated injury [32]. To test the hypothesis that excessive IGFBP3 in hypocretin cells contributes to this cell death, we crossed Hcrt-ataxin-3 transgenic mice (animals with targeted cell death 2-4 weeks after birth) with transgenic mice overexpressing human IGFBP3 (hIGFBP3), but found no effects on the speed of hypocretin cell death. The lack of effects of IGFBP3 on cell death in this model might be due to the differences in circulating vs hypocretin cell specific IGFBP3 overexpression, or to lack of an IGFBP3 effect in the context of ataxin-induced cell degeneration, but is consistent with the notion that IGFBP3 may be proapoptotic only in specific circumstances, such as cancerous cells.
###end p 66
###begin p 67
###xml 203 211 203 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 216 223 216 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 249 256 249 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 402 411 402 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g003">Fig. 3A&#8211;C</xref>
###xml 543 547 543 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Silha2">[33]</xref>
###xml 553 561 553 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 605 609 605 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HCRT</italic>
###xml 629 636 629 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g003">Fig. 3E</xref>
###xml 793 800 793 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g003">Fig. 3F</xref>
###xml 853 863 853 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hmutIGFBP3</italic>
###xml 1100 1106 1100 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Igfbp3</italic>
###xml 257 272 <span type="species:ncbi:10090">transgenic mice</span>
###xml 782 787 <span type="species:ncbi:9606">human</span>
###xml 1116 1120 <span type="species:ncbi:10090">mice</span>
The results above do not support the involvement of IGFBP3 in causing hypocretin cell death in narcolepsy. We therefore next explored whether IGFBP3 modulates hypocretin transmission, with complementary in vitro and in vivo functional studies using hIGFBP3 transgenic mice. We found that increased IGFBP3 decreases both hypocretin mRNA, and hypocretin peptide content in hypothalamus and target areas (Fig. 3A-C). Although these effects could be indirectly mediated by minor endocrine abnormalities in these animals, for example hyperglycemia [33], the in vitro findings that IGFBP3 expression suppresses HCRT promotor activity (Fig. 3E) and that the functional IGFBP3 polymorphism rs2854744 is associated with reduced hypocretin transmission, observed as lower levels of Hcrt-1 in human CSF (Fig. 3F), makes this hypothesis unlikely. Overexpression of hmutIGFBP3, a mutant form that does not bind IGF, also reduces hypocretin peptide content in brainstem but not in hypothalamus suggesting both IGF dependent and independent effects on hypocretin transmission. Hypocretin transmission was normal in Igfbp3 knockout mice, potentially reflecting functional redundancy among the 7 known IGFBP family members.
###end p 67
###begin p 68
###xml 115 122 115 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 123 138 <span type="species:ncbi:10090">transgenic mice</span>
###xml 359 365 <span type="species:ncbi:9606">humans</span>
Increased IGFBP3 expression (which was stable across the 24 hrs) was shown to have functional effects on sleep, as hIGFBP3 transgenic mice slept significantly more prior to light onset. It is notable that the effect was primarily observed at the end of the active period. As hypocretin release is highest at this time of the day (equivalent to the evening in humans), higher IGFBP3 levels may affect hypocretin transmission only at times of highest demand, through the reduction of releasable peptide stores in terminals.
###end p 68
###begin p 69
###xml 76 80 76 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Bunn1">[16]</xref>
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Carskadon1">[34]</xref>
###xml 348 352 348 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Schneider1">[35]</xref>
###xml 354 358 354 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Obal1">[36]</xref>
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Carskadon1">[34]</xref>
IGFBP3 and IGF serum levels are highest around puberty, and drop thereafter [16], [34]. It is thus interesting to speculate that increased sleepiness during puberty could coincide with peak IGFBP3 levels. Most work to date has focused on the studies of Growth Hormone, the primary determinant of IGF, while the effects of IGF on sleep seem complex [35], [36]. Additional investigations of the chronic effects of IGFs and IGFBP3 on sleep changes around puberty are needed [34]. IGFBP3, together with IGF, is to be added to the growing list of metabolic indicators that have been reported to regulate hypocretin activity.
###end p 69
###begin p 70
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 107 112 <span type="species:ncbi:9606">human</span>
In summary, this study exemplifies the successful use of human postmortem brain for microarray analysis of human neuropathology. The analysis not only confirmed known genes colocalized with hypocretin cells but also identified a new candidate with functional relevance to hypocretin cell physiology and sleep regulation. This factor, IGFBP3, is only expressed at high levels in a few neuronal cell groups besides hypocretin cells, and regulates hypocretin transcription. We hypothesize that increased IGFBP3 amount in HCRT cells decreases HCRT production and reduces wake under physiological conditions. When expression exceeds a specific threshold however, it may initiate hypocretin cell death and cause narcolepsy.
###end p 70
###begin title 71
Materials and Methods
###end title 71
###begin title 72
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human studies
###end title 72
###begin title 73
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human samples
###end title 73
###begin p 74
###xml 374 381 374 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t001">Table 1</xref>
###xml 406 415 406 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DQB1*0602</italic>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 384 392 <span type="species:ncbi:9606">Patients</span>
###xml 589 594 <span type="species:ncbi:9606">child</span>
###xml 791 796 <span type="species:ncbi:9606">human</span>
All blood and DNA samples were of Caucasian origin. Narcolepsy and control brain donors were primarily recruited through the Stanford narcolepsy brain donation program and the Stanford Brain Bank. Samples from 9 narcoleptic patients (89% Caucasian) and 14 Caucasian controls were dissected. Six narcolepsy and 11 control samples were analyzed after passing quality control (Table 1). Patients were all HLA DQB1*0602 positive with cataplexy. Sera from 11 narcolepsy and 11 controls, CSF from 27 narcolepsy and 35 controls were also used for IGFBP3 measurements. DNA samples from 130 parent-child trios (proband and parents), and 252 individuals with available CSF hypocretin level values in the control range, were obtained and used. Informed consent was obtained in accordance with Stanford human subjects policy and the principles of the Declaration of Helsinki.
###end p 74
###begin title 75
Brain dissection
###end title 75
###begin p 76
###xml 469 473 463 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Mai1">[37]</xref>
###xml 515 519 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Paxinos1">[38]</xref>
###xml 445 450 <span type="species:ncbi:9606">human</span>
Four brain regions were dissected: posterior and anterior hypothalamus, LC and diagonal band of Broca. Coronal sections (0.9 mm) of hypothalamus and diagonal band, and transaxial brainstem sections were cut from frozen blocks, mounted, and stored at -80degreesC. Digital photographs of the blocks were used for orientation and identification of target regions. The location of hypothalamic structures and the diagonal band were determined using human atlas coordinates [37]. The LC was identified by atlas location [38] and coloration.
###end p 76
###begin p 77
Posterior hypothalamic samples were collected from the mammillary body (atlas fig.32, optic chiasm +13 mm) to the level where the fornix enters the hypothalamus (fig. 25, optic chiasm +4 mm). Anterior hypothalamic samples were collected from this level (fig. 24, optic chiasm +3 mm) to the optic chiasm (fig. 19, optic chiasm -2 mm). Diagonal band areas closely surrounded the anterior hypothalamus in the same planes. Hypothalamic and diagonal band samples were dissected by scalpel, LC samples were collected with a 1.2 mm Palkovits punch (Stoelting Co., Wood Dale, IL).
###end p 77
###begin title 78
RNA isolation and Array Hybridization
###end title 78
###begin p 79
Biotinylated cDNA synthesized from total RNA was hybridized to microarrays (HG-U133 A and B, Affymetrix, Santa Clara, CA) according to manufacturer protocols (Genechip manual, Affymetrix). Fluorescent array images were scanned (Affymetrix GeneArray 2500 or GeneChip 3000 scanner) and analyzed with global scaling, adjusting mean target intensity to 500 for all probe sets (Affymetrix MAS 5.0 software).
###end p 79
###begin title 80
Quality control and sample comparisons
###end title 80
###begin p 81
###xml 152 156 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Tomita1">[39]</xref>
###xml 419 424 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
The pH of each sample was measured (homogenate of a 10x dilution of 0.5 g of temporal cortex or striatum in water). Samples with pH</=6.5 were excluded [39]. Integrity of extracted RNA was verified by RNA nano LabChips on a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Samples with a 28S/18S ratio below 0.5 were discarded (median ratio 0.81). Microarray data was also used to estimate RNA quality (ratio of GAPDH 3' over 5' probe hybridization). Samples with a ratio over 8 were excluded (median ratio 2.3). Postmortem interval had less effect on RNA quality and subjects were included independent of interval (median 7 hrs, all below 48 hrs).
###end p 81
###begin p 82
###xml 130 139 126 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DQB1*0602</italic>
###xml 435 444 427 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DQB1*0602</italic>
###xml 532 541 520 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DQB1*0602</italic>
###xml 623 630 611 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t001">Table 1</xref>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
We compared regional transcript abundance in 11 control brains (74.0+/-13.0 years old, PMI: 14.1+/-17.0 hr, 63.6% male, 36.4% HLA DQB1*0602 positive). Sample size for brain regions (varied due to availability and sample quality) included 8 posterior hypothalami, 6 anterior hypothalami, 7 diagonal bands and 4 LCs. We compared posterior hypothalami of 6 narcoleptic patients (68.8+/-12.3 years old, PMI 15.7+/-16.3 hr, 33.3% male, all DQB1*0602 positive) and 8 controls (73.0+/-13.0 years old, PMI 11.8+/-15.0 hr, 62.5% male, 37.5% DQB1*0602 positive) for the A chip, and 5 narcolepsy and 7 control samples for the B chip (Table 1). Overall mean age, PMI and sex did not differ significantly.
###end p 82
###begin title 83
Statistical analysis of array data
###end title 83
###begin p 84
###xml 494 496 494 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs</italic>
###xml 623 624 623 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
MAS 5.0 was used for signal calculation and present/absent determination combined with SAM ranking analysis to identify significantly up/down regulated genes. Data from the A and B chips were analyzed separately. Probes with an absent or marginal call in more than 90% of samples were omitted as were array tags linked to multiple genes, and only the highest SAM ranked probe for a gene was included. Filtering eliminated 41% and 53% of the transcripts from the A and B chips in the narcolepsy vs control comparison. Results were reported as SAM rankings, fold changes in average expression levels, and Mann-Whitney U-test p-values. The top 15 SAM upregulated genes were used for comparisons across brain regions. Genes upregulated in two of three comparisons were reported. For the comparison of posterior hypothalamus between narcolepsy and control, the top 100 SAM up or down regulated candidates were selected and sorted based on fold changes: those above 2.5 or below 0.4 fold change were studied further.
###end p 84
###begin title 85
Quantitative Reverse Transcriptase PCR
###end title 85
###begin p 86
###xml 329 333 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Vandesompele1">[40]</xref>
###xml 649 653 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CART</italic>
###xml 653 657 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Broberger1">[41]</xref>
###xml 659 662 647 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAL</italic>
###xml 662 666 650 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Hakansson1">[42]</xref>
###xml 668 672 656 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PDYN</italic>
###xml 672 675 660 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Chou1">[9]</xref>
###xml 680 685 668 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NPTX2</italic>
###xml 685 689 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Reti1">[10]</xref>
Candidate transcripts were studied by QRT-PCR (ABI 7300 system, Applied Biosystems, Foster City, CA). cDNA was synthesized from total RNA using Superscript III Reverse Transcriptase and random hexamer.(Invitrogen, Carlsbad, CA). Geometric means of beta-actin and beta2-microglobulin were used for normalization (geNorm analysis) [40]. After performing QRT-PCR for selected genes in parallel with beta-actin and beta2-microglobulin, relative expression quantity was calculated. Genes were considered validated when the mean fold change was more than 1.5 and Mann-Whitney U-test indicated statistical significance (p<0.05). Expression differences for CART[41], GAL[42], PDYN[9] and NPTX2[10] were also verified.
###end p 86
###begin title 87
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human brain immunohistochemistry
###end title 87
###begin p 88
###xml 287 288 277 278 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 289 290 279 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 420 424 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Taheri1">[43]</xref>
###xml 1055 1056 1045 1046 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1057 1058 1047 1048 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 343 348 <span type="species:ncbi:9796">horse</span>
###xml 376 381 <span type="species:ncbi:10090">mouse</span>
###xml 528 533 <span type="species:ncbi:9796">horse</span>
###xml 539 544 <span type="species:ncbi:10090">mouse</span>
###xml 818 824 <span type="species:ncbi:9986">rabbit</span>
###xml 837 841 <span type="species:ncbi:9925">goat</span>
###xml 926 932 <span type="species:ncbi:9986">rabbit</span>
###xml 938 942 <span type="species:ncbi:9925">goat</span>
Six hypothalami (4 control, 2 narcolepsy) were fixed in 4% paraformaldehyde (PFA, pH 7.3), cryoprotected and sectioned coronally to obtain a series of 24 sections (40 microm). The following steps were performed at 4degreesC interspersed with washes. Sections were (I) treated with 0.3% H2O2, (II) post-fixed with 4% PFA, (III) blocked in 1.5% horse serum, (IV) incubated with mouse anti-HCRT monoclonal antibody (1:250) [43] or a monoclonal anti-NeuN antibody (1:50,000;Millipore, Billerica, MA) (V) incubated with biotinylated horse anti-mouse IgG (1:200; Vector Laboratories, Burlingame, CA), (VI) alkaline phosphatase (AP) conjugated ABC (1:100; Vector), and (VII) VectaRed AP-substrate (1:50; Vector) in 0.1 M Tris-HCl (pH 8.4) until satisfactory staining was obtained. Sections were then (VIII) incubated in 1.5% rabbit serum, (IX) goat anti-IGFBP3 antiserum (1:250; AF675 R&D Systems, Minneapolis, MN), (X) biotinylated rabbit anti-goat IgG (1:200, Vector), (XI) ABC reagent (1:100; Vector), (XII) biotinyl-tyramide (1:500; PerkinElmer) with 0.03% H2O2, and (XIII) Qdot 525 streptavidin conjugate (1:100;Invitrogen) in borate buffer (pH 8.5). Sections were mounted and analyzed under a fluorescence microscope equipped with a CCD camera: images were digitally merged to visualize the colocalization of signals.
###end p 88
###begin title 89
Evaluation of hypocretin and IGFBP3 levels, antibodies and IGFBP3 genotyping
###end title 89
###begin p 90
###xml 324 327 324 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Mignot2">[2]</xref>
CSF and serum IGFBP3 levels were measured in duplicate using a total ELISA kit (DSL-10-6600; Diagnostic Systems Laboratories, Webster, TX) according to the manufacturer's protocol. Average intra-assay coefficients of variation were 2.5%. CSF hypocretin-1 levels were measured using a radioimmunoassay as reported previously [2]. We tested CSF of 27 narcolepsy and 35 matched controls, and serum from 11 narcolepsy and 11 controls.
###end p 90
###begin p 91
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
Full length IGFBP3 cDNA (EcoR1-ApaI fragment, clone 5287665, Invitrogen) was subcloned into pCMV-Tag3 and transfected into COS-1 cells (Lipofectamine 2000, Invitrogen). Protein was extracted from cells and culture medium by standard methods (RIPA buffer, and protocol Sigma, St. Louis, MO).
###end p 91
###begin p 92
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 202 213 <span type="species:ncbi:3704">horseradish</span>
###xml 242 248 <span type="species:ncbi:9793">donkey</span>
###xml 254 258 <span type="species:ncbi:9925">goat</span>
###xml 468 473 <span type="species:ncbi:9606">human</span>
###xml 540 546 <span type="species:ncbi:9793">donkey</span>
###xml 552 557 <span type="species:ncbi:9606">human</span>
Protein extracts were run on 10% SDS-PAGE gels, transferred onto nitrocellulose, and incubated with anti-human IGFBP3 polyclonal antiserum (1:200; Santa Cruz Biotechnology, Santa Cruz, CA), followed by horseradish peroxidase (HRP)-conjugated donkey anti-goat IgG (1:4000) and then detected with Supersignal West Pico chemiluminescence reagent (ThermoFisher, Wyman, MA), revealing the 42 kDa IGFBP3 band. Similar membranes were used to detect anti IGFBP3 antibodies in human sera. Membranes were incubated with serum (1:200) followed by HRP-donkey anti-human antiserum (1:5000), and chemiluminescent detection. Twenty two narcolepsy and 20 control samples were tested.
###end p 92
###begin p 93
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 237 241 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Jernstrom1">[17]</xref>
The single base pair polymorphism in the IGFBP3 promoter (rs2854744, -202 A/C) was genotyped in 130 Caucasian narcolepsy-cataplexy trios and 262 adult Caucasian subjects (54% females; mean age 35.8+/-0.8 years) using established methods [17].
###end p 93
###begin title 94
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse studies
###end title 94
###begin title 95
Animals and tissue preparation
###end title 95
###begin p 96
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 171 175 171 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hcrt</italic>
###xml 224 231 224 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mIgfbp3</italic>
###xml 352 356 352 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Ning1">[18]</xref>
###xml 408 415 408 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hIGFBP3</italic>
###xml 552 562 552 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hmutIGFBP3</italic>
###xml 661 665 661 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Modric1">[19]</xref>
###xml 790 796 790 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 15 20 <span type="species:ncbi:10090">mouse</span>
###xml 58 73 <span type="species:ncbi:10090">transgenic mice</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 358 373 <span type="species:ncbi:10090">transgenic mice</span>
###xml 389 394 <span type="species:ncbi:9606">human</span>
###xml 445 460 <span type="species:ncbi:10090">transgenic mice</span>
###xml 514 519 <span type="species:ncbi:9606">human</span>
###xml 682 687 <span type="species:ncbi:10090">mouse</span>
###xml 784 789 <span type="species:ncbi:9606">human</span>
###xml 827 832 <span type="species:ncbi:10090">mouse</span>
###xml 968 972 <span type="species:ncbi:10090">mice</span>
###xml 1059 1063 <span type="species:ncbi:10090">Mice</span>
Five different mouse lines were used: hypocretin-ataxin-3 transgenic mice lacking hypocretin neurons (Hcrt-ataxin-3: C57BL/6J background), preprohypocretin knockout mice (Hcrt KO: C57BL/6J background), IGFBP3 knockout mice (mIgfbp3 KO: C57BL/6J background) (courtesy of Dr JE Pintar, University of Medicine and Dentistry of New Jersey, Piscataway, NJ) [18], transgenic mice overexpressing human IGFBP3 cDNA (hIGFBP3 transgenic: CD1 background), transgenic mice overexpressing the Gly56/Gly80/Gly81 mutated form of human IGFBP3 which lacks IGF binding (hmutIGFBP3 transgenic: CD1 background) (courtesy of Dr. LJ Murphy, University of Manitoba, Winnipeg, Canada) [19]. The latter two mouse strains allow differentiation between IGF-bound and IGF-independent effects of the protein. Two human IGFBP3 genes were driven by the same mouse phosphoglycerate kinase I promotor, and were used to distinguish the effect of IGF binding. In all transgenic comparisons, age matched mice of the corresponding genetic background, usually littermates, were used at all times. Mice were maintained under controlled temperature (21+/-1degreesC) and 12 h:12 h light-dark cycle with free access to food and water. The entire study was approved and conducted in accordance with the guidelines of Stanford's Administrative Panel for Laboratory Animal Care.
###end p 96
###begin p 97
###xml 29 33 <span type="species:ncbi:10090">mice</span>
For neuroanatomical studies, mice were euthanized (pentobarbital) and perfused transcardially with saline followed by 50 ml 10% formalin (pH 7.4). Brains were fixed in 10% formalin, and equilibrated with 20% sucrose/0.5% formalin. Coronal slices (30 microm) containing the whole hypothalamus were sectioned into a 1:5 series and mounted.
###end p 97
###begin title 98
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse microarray experiments
###end title 98
###begin p 99
###xml 152 159 152 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004254.s003">Fig. S1</xref>
###xml 39 54 <span type="species:ncbi:10090">transgenic mice</span>
###xml 264 269 <span type="species:ncbi:10090">Mouse</span>
Groups of 30 wild type and 30 ataxin-3 transgenic mice were used. Perifornical hypothalamic 0.5 mm Palkovits punches encompassing the hypocretin field (Fig. S1) were collected at ZT 22. Biotinylated cRNA was synthesized from total RNA and hybridized to Affymetrix Mouse 430 microarrays and scanned fluorescent array images were analyzed with GeneChip Operating Software (Affymetrix)
###end p 99
###begin title 100
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In situ</italic>
In situ hybridization for candidate genes
###end title 100
###begin p 101
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In situ</italic>
###xml 94 101 94 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t002">Table 2</xref>
###xml 273 275 273 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 69 74 <span type="species:ncbi:10090">Mouse</span>
In situ hybridization was performed on 6-10 week male C57BL/6J mice. Mouse cDNA IMAGE clones (Table 2; Invitrogen) were sequence verified (Bionexus, Oakland, CA) and used. Plasmid DNA was linearized and transcribed with T7, T3 or SP6 polymerases (Promega, Madison, WI) and 35S-UTP (Amersham BioSciences, Piscataway, NJ) or digoxigenin-UTP (Roche Diagnostics, Indianapolis, IN) by standard methods.
###end p 101
###begin p 102
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
Probes were diluted in standard hybridization buffer to 3x106 counts per 125 microl. Sections were pretreated in citrate buffer (pH 6.0), and hybridized with probe at 54degreesC, followed by RNase A treatment and stringent washes (2xSSC at 50degreesC; 0.2xSSC, 55degreesC; 0.2xSSC, 65degreesC), dehydrated and exposed to films for 1-40 days.
###end p 102
###begin title 103
In situ hybridization of IGFBP3 and HCRT immunostaining
###end title 103
###begin p 104
###xml 105 110 <span type="species:ncbi:9940">sheep</span>
###xml 197 202 <span type="species:ncbi:9940">sheep</span>
Digoxigenin-labeled probe (1:500) was used in hybridizations as described. Sections were treated with 3% sheep serum/0.1% Triton X-100, and incubated overnight with alkaline phosphatase-conjugated sheep anti-digoxigenin antibodies (1:5000; Roche). Endogenous alkaline phosphatase was blocked (levamisole) and hybridization was visualized by incubation in 0.3 mg/ml NBT(nitroblue tetrazolium) and 0.2 mg/ml BCIP(5-bromo,4-choloro,3-indolylphosphate).
###end p 104
###begin p 105
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 81 87 <span type="species:ncbi:9986">rabbit</span>
###xml 129 134 <span type="species:ncbi:9606">human</span>
###xml 212 216 <span type="species:ncbi:9925">goat</span>
###xml 222 228 <span type="species:ncbi:9986">rabbit</span>
Sections with satisfactory IGFBP3 signal were immunostained with highly specific rabbit anti-HCRT-1 antiserum (1:4000; made with human HCRT-1 as immunogen). Slides were washed and incubated with (I) biotinylated goat anti-rabbit IgG (1:500; Jackson Immunoresearch, West Grove, PA), (II) ABC complex (1:1000; Vector), (III) biotinylated tyramide diluted 1:50 in amplification buffer (Perkin Elmer), (IV) Alexa Fluor-conjugated streptavidin (1:200;Invitrogen).
###end p 105
###begin p 106
To stain and count hypocretin cell populations, successive sections encompassing the entire hypocretin field were stained using an anti HCRT-1 antiserum as described above. Cells were counted without corrections and blind of genotype status.
###end p 106
###begin title 107
Hypocretin-1 radioimmunoassay
###end title 107
###begin p 108
###xml 478 481 472 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
###xml 543 547 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Lin2">[44]</xref>
Frozen brain tissue of animals sacrificed at Zeitbeger time ZT2-ZT3 were extracted with 1 mL of 0.5 M acetic acid and boiled in water bath for 15 minutes. Samples were cooled on ice and centrifuged at 5000xg for 10 minutes. Protein concentration in the supernatant was measured using the Bradford method (Bio-Rad Laboratories, Hercules, CA). The supernatants were dried overnight at 50degreesC and reconstituted in RIA buffer for radioimmunoassay using a commercially available 125I RIA kit (Phoenix Pharmaceuticals, Belmont, CA) as described [44]. The hypocretin contents were corrected against protein concentrations.
###end p 108
###begin title 109
###xml 18 24 <span type="species:ncbi:10090">murine</span>
###xml 25 30 <span type="species:ncbi:9606">human</span>
Preprohypocretin, murine/human IGFBP3 and MCH mRNA quantification
###end title 109
###begin p 110
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 199 205 <span type="species:ncbi:10090">murine</span>
###xml 206 211 <span type="species:ncbi:9606">human</span>
Total RNA from mice hypothalamic regions with RNA extraction reagents (Qiagen, Valencia, CA) and synthesized cDNA was subjected to TaqMan real time PCR analysis to measure relative preprohypocretin, murine/human IGFBP3, and MCH expression levels in parallel with ss-actin, hypoxanthine-guanine phosphoribosyltransferase (HPRT) and GAPDH as internal controls. HPRT was chosen for data normalization due to its stable expression across the genotypes.
###end p 110
###begin title 111
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse sleep recording and analysis
###end title 111
###begin p 112
###xml 1106 1110 1106 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Zhang1">[45]</xref>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 574 578 <span type="species:ncbi:10090">Mice</span>
Nine wild type (WT) and 13 transgenic (TG) mice (age 3-6 months) were implanted under isofluorane anesthesia with telemetry transmitters (ETA-F20, 3.9 g weight, Data Science International, St. Paul, MN) capable of acquiring and sending electroencephalograph (EEG), temperature, and movement data. The two EEG electrodes were secured with dental cement at the following coordinates: anterior/posterior from bregma (AP) 1.5 mm, lateral (ML) 1.5 mm and AP -3.5 mm, ML -3 mm. An analgesic (5 mg/kg Carprofen) and antibiotics (5 mg/kg/day enrofloxacin) was given subcutaneously. Mice were allowed to fully recover for a minimum of two weeks before the experiments. Animals were recorded for a 48-hour period, with the first 24 h undisturbed, followed by 6 h wake extension by gentle handling, and 18 h undisturbed recovery. EEG was sampled at 250 Hz, and the other parameters were sampled at 50 Hz using DataQuest A.R.T. 3.1 (Data Science International, St. Paul, MN). Recordings were scored manually in 10 second epochs using SleepSign (Kissei America, Irvine, CA) according to the method developed previously [45].
###end p 112
###begin title 113
Hypocretin promoter studies
###end title 113
###begin title 114
Cell culture
###end title 114
###begin p 115
###xml 357 358 351 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 6 11 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 73 78 <span type="species:ncbi:9606">human</span>
###xml 207 213 <span type="species:ncbi:9913">bovine</span>
###xml 242 247 <span type="species:ncbi:9606">human</span>
###xml 313 318 <span type="species:ncbi:9796">horse</span>
HeLa (human cervical carcinoma), SF126 (human glioblastoma), and Becker (human astrocytoma) cells were grown in Dulbecco's modified Eagle's medium (DMEM; GIBCO, Grand Island, NY) supplemented with 10% fetal bovine serum (GIBCO),.and SH-SY5Y (human neuroblastoma) cells were grown in DMEM/F12 supplemented with 5% horse serum (GIBCO), at 37degreesC and 5% CO2.
###end p 115
###begin title 116
Reporter plasmids
###end title 116
###begin p 117
###xml 356 360 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004254-Sakurai2">[46]</xref>
###xml 429 465 429 465 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- ccgctcgagGGTGTCTGGCGCTCAGGGTG-3&#8242;</named-content>
###xml 579 616 579 616 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CGACGCGTGGATCCAGATGCCTCTGAATAG-3&#8242;</named-content>
###xml 551 556 <span type="species:ncbi:9606">human</span>
The pGL3-basic plasmid (Promega) encoding the firefly luciferase gene was used for the promoter activity assessment with introduced sequence and the pRL-TK plasmid (Promega) encoding Renilla luciferase was used as internal control for transfection efficiency. The plasmid 3.2 kb Hcrt/pGL3 was constructed by cloning the HCRT promoter sequence at -3278/+87 [46] into upstream of the firefly luciferase gene in pGL3-Basic plasmid; 5'- ccgctcgagGGTGTCTGGCGCTCAGGGTG-3' (corresponds to the first exon sequence just before the translation initiator ATG of human prepro-Hcrt gene, and 5'- CGACGCGTGGATCCAGATGCCTCTGAATAG-3' (-3278) were used.
###end p 117
###begin title 118
Transient transfection
###end title 118
###begin p 119
Cells were seeded at a 250,000 per well in 24-well cell culture plate coated with collagen type I (BD Biosciences, Bedford MA) one day before transfection. Cells were co-transfected with three types of plasmid mixed in the following amount per well with FuGENE 6 Transfection Reagent (Roche): 200 ng firefly luciferase-encoding reporter plasmid (pGL3-basic or 3.2 kb Hcrt/pGL3), 20 ng Renilla luciferase-encoding internal control reporter plasmid (pRL-TK), and 200 ng expression vector (pCMV-Tag3 as mock or IGFBP3/pCMV-Tag3).
###end p 119
###begin title 120
Luciferase activity measurements
###end title 120
###begin p 121
At 24 h after transfection, cells were washed and lysed with 100 microL passive lysis buffer (Promega). Activities of two luciferases encoded by reporter plasmids and internal control plasmids were measured sequentially twice using the Dual-Luciferase Reporter assay reagents (Promega) and PLATE CHAMELEON multilabel platereader (HIDEX, Finland) according to the manufacturer's protocol. Relative luciferase activity (RLA) was determined by FLU value divided by RLU value. All RLA values were further standardized by the reference RLA value for pGL3-basic plasmid with pCMV-Tag3 vector (mock) as 1.0.
###end p 121
###begin title 122
Supporting Information
###end title 122
###begin p 123
###xml 679 686 679 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">methods</xref>
###xml 62 67 <span type="species:ncbi:9606">human</span>
Cross-regional comparison of transcript abundance in selected human brain regions. Comparison of microarray expression data across 4 brain regions in control subjects The listed genes have enriched expression in the indicated region, as compared to the other regions. For example, PMCH gene expression was increased 73.8 fold in the posterior hypothalamus when compared to the anterior hypothalamus and ranked #1 using the SAM analysis. Similarly, PMCH gene expression in the posterior hypothalamus ranked first versus the diagonal band sample (3.3 fold change), and the LC (275.1 fold change). Only genes enriched in one region versus at least two other regions are listed (see methods).
###end p 123
###begin p 124
(0.13 MB DOC)
###end p 124
###begin p 125
Click here for additional data file.
###end p 125
###begin p 126
###xml 279 285 279 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g004">Fig. 4</xref>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
Overall sleep parameters in mice overexpressing human IGFBP3 (TG) versus wild type littermates (WT)Although total wake is decreased in TG mice, the difference is not statistically significant. Hour by hour analysis revealed that decreased wake occurred prior to light onset (see Fig. 4).
###end p 126
###begin p 127
(0.06 MB DOC)
###end p 127
###begin p 128
Click here for additional data file.
###end p 128
###begin p 129
###xml 610 617 610 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004254-t003">Table 3</xref>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 174 189 <span type="species:ncbi:10090">transgenic mice</span>
###xml 285 290 <span type="species:ncbi:10090">mouse</span>
###xml 378 393 <span type="species:ncbi:10090">transgenic mice</span>
Perifornical hypothalamic region dissected for microarray analysis in mice (A) and transcript abundance distribution plots correlating abundance in wild type versus ataxin-3 transgenic mice (B). (A) Immunocytochemistry of hypocretin in wild type (WT, top) and Hcrt-ataxin-3 transgenic mouse (bottom). The area collected using punches is outlined by a circle in wild type versus transgenic mice lacking most hypocretin cells. Transcript abundance distribution (B) in both genotypes is highly correlated, and hypocretin is one of the outliers (circled dot). For list of differentially regulated transcripts, see Table 3.
###end p 129
###begin p 130
(1.56 MB TIF)
###end p 130
###begin p 131
Click here for additional data file.
###end p 131
###begin p 132
###xml 231 237 231 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004254-g004">Fig. 4</xref>
###xml 68 83 <span type="species:ncbi:10090">transgenic mice</span>
###xml 175 190 <span type="species:ncbi:10090">transgenic mice</span>
Locomotion (A) and temperature (B) in wild type (WT) versus hIGFBP3 transgenic mice (Tg). Note decreased temperature and locomotion at the end of the active period in hIGFBP3 transgenic mice, mirroring changes in sleep depicted in Fig. 4.
###end p 132
###begin p 133
(5.70 MB TIF)
###end p 133
###begin p 134
Click here for additional data file.
###end p 134
###begin title 135
References
###end title 135
###begin article-title 136
Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups.
###end article-title 136
###begin article-title 137
The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
###end article-title 137
###begin article-title 138
Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.
###end article-title 138
###begin article-title 139
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.
###end article-title 139
###begin article-title 140
The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.
###end article-title 140
###begin article-title 141
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.
###end article-title 141
###begin article-title 142
###xml 99 104 <span type="species:ncbi:9606">human</span>
A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.
###end article-title 142
###begin article-title 143
###xml 40 45 <span type="species:ncbi:9606">human</span>
Reduced number of hypocretin neurons in human narcolepsy.
###end article-title 143
###begin article-title 144
Orexin (hypocretin) neurons contain dynorphin.
###end article-title 144
###begin article-title 145
Selective expression of Narp, a secreted neuronal pentraxin, in orexin neurons.
###end article-title 145
###begin article-title 146
###xml 23 28 <span type="species:ncbi:9606">human</span>
Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy.
###end article-title 146
###begin article-title 147
Concomitant loss of dynorphin, NARP, and orexin in narcolepsy.
###end article-title 147
###begin article-title 148
###xml 67 72 <span type="species:ncbi:9606">human</span>
Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy.
###end article-title 148
###begin article-title 149
The frustrating and mostly fruitless search for an autoimmune cause of narcolepsy.
###end article-title 149
###begin article-title 150
Significance analysis of microarrays applied to the ionizing radiation response.
###end article-title 150
###begin article-title 151
###xml 139 147 <span type="species:ncbi:9606">children</span>
Early developmental changes in IGF-I, IGF-II, IGF binding protein-1, and IGF binding protein-3 concentration in the cerebrospinal fluid of children.
###end article-title 151
###begin article-title 152
###xml 180 185 <span type="species:ncbi:9606">women</span>
Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women.
###end article-title 152
###begin article-title 153
###xml 69 73 <span type="species:ncbi:10090">mice</span>
Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5.
###end article-title 153
###begin article-title 154
###xml 92 107 <span type="species:ncbi:10090">transgenic mice</span>
Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice.
###end article-title 154
###begin article-title 155
###xml 91 106 <span type="species:ncbi:10090">transgenic mice</span>
Overexpression of gly56/gly80/gly81-mutant insulin-like growth factor-binding protein-3 in transgenic mice.
###end article-title 155
###begin article-title 156
Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77.
###end article-title 156
###begin article-title 157
###xml 42 47 <span type="species:ncbi:9606">human</span>
Systematic analysis of gene expression in human brains before and after death.
###end article-title 157
###begin article-title 158
The specification of noradrenergic locus coeruleus (LC) neurones depends on bone morphogenetic proteins (BMPs).
###end article-title 158
###begin article-title 159
Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.
###end article-title 159
###begin article-title 160
Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses.
###end article-title 160
###begin article-title 161
Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization.
###end article-title 161
###begin article-title 162
###xml 92 95 <span type="species:ncbi:10116">rat</span>
Co-ordinated and cellular specific induction of the components of the IGF/IGFBP axis in the rat brain following hypoxic-ischemic injury.
###end article-title 162
###begin article-title 163
IGFBPs and cancer.
###end article-title 163
###begin article-title 164
###xml 132 137 <span type="species:ncbi:9606">human</span>
Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells.
###end article-title 164
###begin article-title 165
###xml 91 96 <span type="species:ncbi:9606">human</span>
Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus.
###end article-title 165
###begin article-title 166
Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis.
###end article-title 166
###begin article-title 167
Excitotoxic degeneration of hypothalamic orexin neurons in slice culture.
###end article-title 167
###begin article-title 168
###xml 77 92 <span type="species:ncbi:10090">transgenic mice</span>
Impaired glucose homeostasis in insulin-like growth factor-binding protein-3-transgenic mice.
###end article-title 168
###begin article-title 169
Regulation of adolescent sleep: implications for behavior.
###end article-title 169
###begin article-title 170
Central effects of the somatotropic system.
###end article-title 170
###begin article-title 171
The somatotropic axis and sleep.
###end article-title 171
###begin article-title 172
###xml 121 126 <span type="species:ncbi:9606">human</span>
Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain.
###end article-title 172
###begin article-title 173
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.
###end article-title 173
###begin article-title 174
Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems.
###end article-title 174
###begin article-title 175
Leptin receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus.
###end article-title 175
###begin article-title 176
The development of monoclonal antibodies against hypocretin-1 (orexin A).
###end article-title 176
###begin article-title 177
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
Measurement of hypocretin/orexin content in the mouse brain using an enzyme immunoassay: the effect of circadian time, age and genetic background.
###end article-title 177
###begin article-title 178
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy.
###end article-title 178
###begin article-title 179
###xml 26 31 <span type="species:ncbi:9606">human</span>
Structure and function of human prepro-orexin gene.
###end article-title 179
###begin p 180
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 180
###begin p 181
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by NIH-MH073435 to E. Mignot and by the Ministry of Education, Science, Sports and Culture, Grant-in-Aid for Scientific Research 19390310, 1739034 and Science Research on Priority Areas "Comprehensive Genomics" and in part by Uehara Memorial Foundation to M. Honda. E. Mignot (Investigator) is funded by the Howard Hughes Medical Institute.
###end p 181

